SubHero Banner

Selzentry® (maraviroc) – Expanded indication, new formulation

November 4, 2016 – The FDA announced Viiv Healthcare’s Selzentry (maraviroc) 20 mg/mL oral solution and 25 mg and 75 mg tablets in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in patients 2 years of age and older weighing at least 10 kg.

Download PDF